These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3098956)

  • 1. Computerized model for evaluating the kinetics of in vitro release of valpromide from controlled-release tablets under nonsink conditions.
    Rubinstein A; Gonen A; Friedman M
    J Pharm Sci; 1986 Oct; 75(10):959-61. PubMed ID: 3098956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers.
    Bialer M; Rubinstein A; Raz I; Abramsky O
    Eur J Clin Pharmacol; 1984; 27(4):501-3. PubMed ID: 6440792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of valpromide in dogs after various modes of administration.
    Bialer M; Rubinstein A
    Biopharm Drug Dispos; 1984; 5(2):177-83. PubMed ID: 6430363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulating Different Dosing Scenarios for a Child-Appropriate Valproate ER Formulation in a New Pediatric Two-Stage Dissolution Model.
    Karkossa F; Krueger A; Urbaniak J; Klein S
    AAPS PharmSciTech; 2017 Feb; 18(2):309-316. PubMed ID: 27909943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms.
    Lu Z; Fassihi R
    AAPS PharmSciTech; 2017 Feb; 18(2):462-472. PubMed ID: 27106916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of a prolonged-release tablet formulation of diclofenac sodium. Part 1: Using chitosan.
    Acartürk F
    Pharmazie; 1989 Aug; 44(8):547-9. PubMed ID: 2594826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissolution kinetics of bezafibrate in two solid forms for oral administration.
    Cadorniga R; Hernanez MT; Negro S; Burgos ML; Molina IT
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():371-8. PubMed ID: 1820910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General class of multiparticulate dissolution models.
    Pedersen PV; Brown KF
    J Pharm Sci; 1977 Oct; 66(10):1435-8. PubMed ID: 925899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-a-day controlled-release dosage form of divalproex sodium II: development of a predictive in vitro drug release method.
    Qiu Y; Garren J; Samara E; Cao G; Abraham C; Cheskin HS; Engh KR
    J Pharm Sci; 2003 Nov; 92(11):2317-25. PubMed ID: 14603516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated potentiometric procedure for studying dissolution kinetics acidic drugs under sink conditions.
    Underwood FL; Cadwallader DE
    J Pharm Sci; 1978 Aug; 67(8):1163-7. PubMed ID: 27630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Versatile kinetic-approach to analysis of dissolution data.
    Pedersen PV; Myrick JW
    J Pharm Sci; 1978 Oct; 67(10):1450-5. PubMed ID: 702301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of a slow-release preparation of valproic acid under steady-state conditions.
    Klotz U
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):24-6. PubMed ID: 6799412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of valpromide.
    Bialer M
    Clin Pharmacokinet; 1991 Feb; 20(2):114-22. PubMed ID: 2029804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.
    Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O
    Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro release testing of matrices based on starch-methyl methacrylate copolymers: effect of tablet crushing force, dissolution medium pH and stirring rate.
    Ferrero C; Jiménez-Castellanos MR
    Int J Pharm; 2014 Jan; 461(1-2):270-9. PubMed ID: 24333902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel diclofenac potassium controlled release tablets by wet granulation technique and the effect of co-excipients on in vitro drug release rates.
    Shah S; Khan GM; Jan SU; Shah K; Hussain A; Khan H; Khan H; Khan H; Khan KA
    Pak J Pharm Sci; 2012 Jan; 25(1):161-8. PubMed ID: 22186325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide].
    Bertschy G; Vandel S; Jounet JM; Allers G
    Encephale; 1990; 16(1):43-5. PubMed ID: 2109680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of valpromide in psychiatric therapeutics].
    Lambert PA; Venaud G
    Encephale; 1987; 13(6):367-73. PubMed ID: 3131112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mathematical method for quantitative expression of deviation from the higuchi model.
    Gohel MC; Panchal MK; Jogani VV
    AAPS PharmSciTech; 2000 Oct; 1(4):E31. PubMed ID: 14727896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.